共 101 条
[1]
Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[2]
Miller KD(2016)More deaths from pancreatic cancer than breast cancer in the EU by 2017 Acta Oncol 55 1158-1160
[3]
Jemal A(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-132
[4]
Ferlay J(2012)Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades Ann Surg Oncol 19 169-175
[5]
Partensky C(2018)Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial Ann Surg 268 215-222
[6]
Bray F(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703
[7]
Chen W(2013)Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study J Clin Oncol 31 1640-1648
[8]
Zheng R(2011)Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer Cancer Chemother Pharmacol 67 249-254
[9]
Baade PD(2018)Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer Cancer Manag Res 10 4805-4815
[10]
Zhang S(2018)Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score) Radiother Oncol 129 313-318